Research
Hormonal
DPP-4 inhibitors reduce systemic inflammation by suppressing the secretion of IL-6 and IL-1β and inhibiting NF-κB nuclear translocation, leading to improved endothelial function and plaque stabilization.
DPP-4 inhibitors (like sitagliptin) help stabilize heart disease plaques by reducing the inflammatory signals (IL-6, IL-1β) that attract immune cells to artery walls. This reduces the risk of plaque rupture and heart attacks.
GoodSupportsHIGH confidence
alogliptin... was shown to suppress toll-like receptor 4-mediated extracellular signal-regulated kinase, IL-6, and IL-1β secretion... sitagliptin’s analogue... showed inhibition of NF-κB p65 nuclear translocation... DPP4is suppress macrophage accumulation and foam cell formation reducing the total aortic atherosclerotic lesions.
Why this rating
Supported by multiple studies including meta-analyses showing reduced CRP.
Source
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Panagiotis Theofilis et al. · Life · 2022
DOI 10.3390/life12111829
narrative_reviewCited 25×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Novel antidiabetic agents, specifically SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, exert significant anti-inflammatory effects in the cardiovascular and renal systems, contributing to improved cardiorenal outcomes in type 2 diabetes.Good
- GLP-1 receptor agonists reduce cardiovascular inflammation by activating AMPK and CAMKKβ signaling pathways, leading to the downregulation of pro-inflammatory genes and increased SIRT6 expression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →